In our previous article on ocular toxicity studies of eye drops, we explored the purpose and experimental design of such trials. This review delves into the specifics of ocular exposure and the local and systemic safety evaluations associated with eye drop administration.
Ocular Exposure
Eye drop formulations vary significantly in their standard concentrations, ranging from 0.001% to 10% (0.01 mg/mL to 100 mg/mL). Upon instillation, eye drops are diluted by tears and partially obstructed by the tear film, especially for compounds with high protein-binding affinity. However, the drug concentration on ocular surface tissues such as the conjunctiva and corneal epithelium can remain markedly high.
In contrast, the bioavailability of drugs in the aqueous humor is typically below 10%. Numerous studies have examined factors influencing the absorption of eye drops. Key chemical properties affecting ocular penetration include hydrophilicity or lipophilicity, ionization status, molecular weight, concentration, and the excipients in the formulation. Once administered, drugs distribute through two primary pathways: (1) the corneal route and (2) the conjunctival/scleral route.
Additionally, recent research has proposed three potential pathways for drug delivery to the retina and choroid:
- Corneal penetration followed by passage through the vitreous.
- Uveoscleral absorption via the corneal route.
- Periocular scleral absorption.
The distribution pathway depends on the physicochemical properties of the compound.
Physiological factors influencing ocular toxicity reactions:
The corneal absorption of drugs is concentration-dependent, limited by the gradient between the drug and the ocular surface. Changes in tear volume, whether related to the drug or external factors (e.g., anesthesia), can alter corneal absorption rates. Blink frequency is another variable; increased blinking accelerates drug clearance from the ocular surface, potentially mitigating or exacerbating toxicity. Furthermore, corneal epithelial damage can enhance the penetration of hydrophilic drugs, increasing local drug exposure and aggravating toxic reactions.
Transport Proteins and Drug Kinetics
Studies have identified transport proteins in various ocular tissues, including the cornea, iris-ciliary body, and retina/choroid. For instance, Zhang et al. (2008) reported that human ocular tissues predominantly express the efflux transporter MRP1 (multidrug resistance-associated protein 1) and uptake transporters such as PEPT1 (peptide transporter 1), OCT1 (organic cation transporter 1), OCTN1, and OCTN2. The influence of these transporters on ocular pharmacokinetics and interspecies variability warrants further investigation.
Ocular distribution differences between the anterior and posterior segments:
Drug exposure levels in the posterior segment, particularly the retina, are substantially lower than those in the anterior segment due to anatomical and functional barriers. However, some eye drops, including brimonidine, difluprednate, and dexamethasone, have demonstrated therapeutic effects in the retina. For example, research on nepafenac suggests that posterior segment penetration primarily occurs via gradual diffusion from periocular tissues through the posterior sclera to the retina and choroid.
Emerging drug delivery systems for posterior segment administration are under development, emphasizing the growing importance of posterior segment safety evaluations in therapeutic innovation.
Ocular Metabolism
Several studies have identified abundant cytochrome P450 enzymes (CYPs) in ocular tissues, although their activity and expression levels are significantly lower than those in major metabolic organs such as the liver.
Ocular Toxicity and Safety Evaluations
The toxicity of eye drops can be classified as primary toxicity, off-target toxicity, or chemical-related effects. Due to the high local concentrations at the administration site, toxic reactions predominantly affect anterior segment tissues such as the cornea, conjunctiva, and iris, as well as periocular structures like the eyelids and lacrimal glands.
Key considerations in anterior segment toxicity:
- Conjunctival Congestion: Commonly observed in ocular instillation toxicity studies (OITSs), congestion can be transient if caused by vasodilation or persistent when associated with tissue damage.
- Corneal Opacity: Of significant toxicological concern, corneal opacity can impair vision and requires recovery-phase investigations to evaluate its reversibility. For instance, corneal epithelial damage is often reversible in rabbits and humans within a week, but limbal stem cell damage may lead to permanent opacity.
- Lens Opacification: Prolonged exposure of the lens to aqueous humor-borne drugs can lead to opacification. In humans, drugs like pilocarpine and acetylcholine have been linked to this condition, often involving complex metabolic disruptions.
- Retinal Toxicity: Systemic drug administration is a more common cause of retinal toxicity compared to topical application. However, certain eye drops have shown pharmacodynamic effects on the retina, highlighting the need for advanced imaging techniques to detect even subtle retinal changes.
Systemic Toxicity in Eye Drop Studies
Although systemic exposure from eye drops is relatively low, drugs absorbed through the nasolacrimal duct into systemic circulation can induce adverse effects. Toxicokinetics (TK) plays a crucial role in assessing systemic exposure levels and correlating ocular findings. For example, systemic side effects in small children, such as cardiovascular or CNS disturbances, have been reported with drugs like atropine and cyclopentolate.
Conclusion
Ocular toxicity studies for eye drops require meticulous planning and safety assessment strategies. Toxicologists must comprehensively evaluate all characteristics of eye drops to ensure both local and systemic safety. With increasing innovation in ocular drug delivery systems, such studies are essential for advancing safe and effective therapies.
Prisys Biotech: Advancing Preclinical Pharmacology with Non-Human Primate Models
Prisys Biotech is a leading Contract Research Organization (CRO) specializing in preclinical pharmacology using non-human primates (NHPs). With a focus on developing advanced animal disease models, we provide high-quality research services that support the drug discovery and development process, enabling our partners to achieve greater success in clinical trials.
Expertise in Non-Human Primate Models
Prisys Biotech offers extensive expertise in the use of non-human primates for pharmacokinetic (PK) and pharmacodynamic (PD) studies. Our models, developed using cynomolgus monkeys, are ideal for evaluating therapeutic efficacy across a wide range of diseases. The biological and behavioral similarities of NHPs to humans provide an accurate and reliable platform for preclinical research, ensuring that our clients obtain relevant and actionable data for drug development.
